Effects of ACEI induced Cough on LV mass in Hypertensive patients and Its Reduction by Antihypertensive Medication

Background and Objectives:Angiotensin-converting enzyme inhibitors have the effect of regression of left ventricular hypertrophy which has been known as the adverse prognostic factor in the cardiovascular diseases. There are some reports that patients having low ACE activity are prone to have the ACE inhibitorinduced cough. In this study we evaluate the difference of the regression of left ventricular mass according to ACE inhibitor induced cough. Materials and Methods:Newly detected hypertensive patients (N=108) from Jan. 1994 to Dec.1997 without cough and other contraindications to ACEI were prospectively prescribed ACEI and followed up for two years whether they have experienced ACE inhibitor induced cough or not. Cough and non-cough group are analyzed the amount of regression of left ventricular mass by ECG. Results:Left ventricular mass index decreases significantly from 128±38 to 119±36 g/m (ΔLVMI=-9±22 g/m, p<0.05), after ACE inhibitors had been used for two years. There is no difference between cough and non-cough group. When subgroup analysis has been done according to sex and the presence of the baseline left ventricular hypertrophy, LVH (+) group and female have the tendency of the larger amount of decreasing of LVMI than LVH (-) group and male respectively [LVH (+):LVH (-)=-15±26:-3±15, M:F=-12±24:-7± 19]. After the adjusting of the influence of baseline LVM and sex, the amount of degree of LVMI regresssion in case of the men without baseline LVH is significantly different in cough and non-cough group. LVMI decreases significantly in non-cough group, but not in cough group. Conclusion:ACE inhibitors have the effect of the regression of LVMI by ECG. The amount of change of LVMI is greater in female and the patients with baseline LVH. In case of men without LVH, non-cough group has larger amount of decreasing of LVMI than cough group. (Korean Circulation J 2000;30(12):1546-1554)

[1]  T Kuznetsova,et al.  Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis , 2000, Journal of Human Hypertension.

[2]  D. Sohn,et al.  Synergistic effect of angiotensin-converting enzyme and angiotensinogen gene on cardiac hypertrophy. , 2000, International journal of cardiology.

[3]  J. Yoshikawa,et al.  Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. , 1999, The American journal of medicine.

[4]  F. Perticone,et al.  Deletion polymorphism of angiotensin-converting enzyme gene and left ventricular hypertrophy in southern Italian patients. , 1997, Journal of the American College of Cardiology.

[5]  A. Gharavi,et al.  Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. , 1996, The American journal of cardiology.

[6]  M. Quiñones,et al.  Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. , 1995, Circulation.

[7]  H. Schunkert,et al.  Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. , 1995, Circulation.

[8]  T. Parrish,et al.  Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. , 1995, Circulation.

[9]  H. Schunkert,et al.  Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. , 1994, The New England journal of medicine.

[10]  Y. Kawakami,et al.  Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough , 1994, The Lancet.

[11]  J. Sadoshima,et al.  Critical Role of the AT1 Receptor Subtype , 2005 .

[12]  D. Ganten,et al.  Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. , 1993, Journal of molecular and cellular cardiology.

[13]  J. Imbs,et al.  Cough and ACE inhibitors , 1993, The Lancet.

[14]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[15]  F. Soubrier,et al.  PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). , 1992, Nucleic acids research.

[16]  E. J. Martinez,et al.  Respiratory Tract Side Effects of Angiotensin Converting Enzyme Inhibitors: Current Knowledge , 1991, Southern medical journal.

[17]  A. Morice,et al.  ACE inhibitor cough: a genetic link? , 1991, The Lancet.

[18]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[19]  K. Baker,et al.  Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. , 1990, The American journal of physiology.

[20]  D. Ganten,et al.  Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[21]  R. Goldszer,et al.  Prevalence of cough during angiotensin-converting enzyme inhibitor therapy. , 1988, The American journal of medicine.

[22]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[23]  A. LaCroix,et al.  Electrocardiographic estimate of left ventricular mass versus radiographic cardiac size and the risk of cardiovascular disease mortality in the epidemiologic follow-up study of the First National Health and Nutrition Examination Survey. , 1988, The American journal of cardiology.

[24]  J. Drazen,et al.  Substance P-induced bronchoconstriction in the guinea pig. Enhancement by inhibitors of neutral metalloendopeptidase and angiotensin-converting enzyme. , 1988, The American review of respiratory disease.

[25]  D. Coulter,et al.  Cough associated with captopril and enalapril. , 1987, British medical journal.

[26]  N. Thornberry,et al.  Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. , 1984, Molecular pharmacology.

[27]  G. Williams,et al.  Angiotensin-converting enzyme inhibition and prostaglandins. , 1982, The American journal of cardiology.

[28]  M. Antonaccio,et al.  The effects of captopril (SQ 14,225) on bradykinin-induced bronchoconstriction in the anesthetized guinea pig. , 1979, European journal of pharmacology.

[29]  H. Coleridge,et al.  Stimulation of ‘irritant’ receptors and afferent C-fibres in the lungs by prostaglandins , 1976, Nature.